Locally Advanced Solid Tumors Clinical Trials

4 recruiting

Locally Advanced Solid Tumors Trials at a Glance

6 actively recruiting trials for locally advanced solid tumors are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in New York, Singapore, and London. Lead sponsors running locally advanced solid tumors studies include Turning Point Therapeutics, Inc., Amgen, and Genentech, Inc..

Browse locally advanced solid tumors trials by phase

Treatments under study

About Locally Advanced Solid Tumors Clinical Trials

Looking for clinical trials for Locally Advanced Solid Tumors? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

TMB-HHistologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
ImmuneOncia Therapeutics Inc.30 enrolled4 locationsNCT06365840
Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled6 locationsNCT07403721
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid Tumors
Genentech, Inc.250 enrolled18 locationsNCT06031441
Recruiting
Phase 1Phase 2

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1Phase 2

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

LymphomaMetastatic Solid TumorsLocally Advanced Solid Tumors+1 more
Turning Point Therapeutics, Inc.75 enrolled68 locationsNCT04094610
Recruiting
Phase 1

A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors

Locally Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.220 enrolled10 locationsNCT07050459